Last updated: November 2, 2026
ARTISS is a fibrin sealant manufactured by Baxter Healthcare for adherence of autologous skin grafts to surgically prepared wound beds, particularly in burn surgery. Its commercial position is supported by an established FDA-approved indication, hospital familiarity, and a specialized use case. Its financial trajectory is difficult to isolate because Baxter does not report ARTISS revenue separately. The product’s principal risks are competition from other fibrin sealants, hospital purchasing pressure, plasma-derived supply requirements, and limited expansion beyond its approved surgical indication.
What is ARTISS and how is it used?
ARTISS is a biologic fibrin sealant containing human fibrinogen and human thrombin. The two components are applied to a wound bed and skin graft, where they form a fibrin clot that helps secure the graft. ARTISS is not primarily positioned as a hemostatic product. Its FDA-approved use is tissue adhesion rather than control of active bleeding.
The U.S. label covers:
| Product attribute |
ARTISS |
| Active components |
Human fibrinogen and human thrombin |
| Product class |
Fibrin sealant, biologic |
| Primary use |
Adherence of autologous skin grafts |
| Key indication |
Surgically prepared wound beds resulting from burns in adults and pediatric patients aged 1 year and older |
| Manufacturer |
Baxter Healthcare Corporation |
| Administration |
Topical application |
| Storage |
Frozen storage, with product-specific handling requirements |
| FDA approval |
2008 |
| U.S. regulatory pathway |
Biologics License Application |
| Orange Book status |
Not listed as a conventional small-molecule drug |
| Biosimilar pathway |
Theoretical 351(k) pathway, but no established ARTISS biosimilar competition has been publicly identified |
ARTISS is sold in different package sizes and delivery configurations. Product handling, thawing, preparation time, spray technique, and operating-room workflow affect utilization and purchasing decisions. The FDA label warns that ARTISS must not be injected intravascularly because intravascular application can create life-threatening thrombotic events (U.S. Food and Drug Administration [FDA], 2023).
When did ARTISS receive FDA approval and lose biologic exclusivity?
ARTISS received FDA approval in 2008. Its statutory 12-year reference-product exclusivity period under the Biologics Price Competition and Innovation Act would have expired approximately in 2020, subject to the precise reference-product licensure date and any applicable pediatric extension.
| Milestone |
Approximate timing |
| FDA approval |
2008 |
| 12-year reference biologic exclusivity |
Approximately 2020 |
| Current status |
Commercially marketed biologic |
| Patent-based market protection |
Not the principal visible barrier to competition |
| Regulatory entry risk |
Limited near-term biosimilar risk, with greater risk from competing fibrin sealants |
Loss of statutory biologic exclusivity does not automatically create immediate competition. A competing manufacturer still needs manufacturing capability, clinical and regulatory support, supply of human plasma-derived inputs, hospital adoption, and a commercially viable delivery system.
ARTISS is not listed in the FDA Orange Book in the same manner as a conventional tablet or injectable small-molecule drug. Orange Book listings generally cover approved drug products and patent information submitted for those products. ARTISS is regulated as a biologic, so the relevant framework is the Public Health Service Act and the Purple Book rather than the conventional abbreviated new drug application and Paragraph IV process (FDA, n.d.-a; FDA, n.d.-b).
What patents protect ARTISS?
Public commercial protection for ARTISS is more likely to depend on manufacturing know-how, formulation control, viral-clearance processes, delivery devices, and regulatory compliance than on a single blocking composition-of-matter patent.
No ARTISS patent estate with a publicly recognized Orange Book listing is apparent. That means a generic-drug Paragraph IV challenge is not the expected route to entry. A competitor would more likely pursue:
- A standalone biologic application.
- A biosimilar application under section 351(k), if analytical and clinical comparability can be established.
- A competing fibrin-sealant product under an independent regulatory strategy.
- A device or delivery-system strategy that avoids Baxter-specific rights.
What formulation and manufacturing barriers affect ARTISS?
ARTISS uses human plasma-derived proteins. Manufacturing barriers include:
- Plasma collection and qualification.
- Donor screening and infectious-disease testing.
- Viral inactivation and removal.
- Control of fibrinogen and thrombin concentration.
- Preservation of biological activity after freezing and thawing.
- Sterile filling and packaging.
- Validation of spray or applicator systems.
- Cold-chain and operating-room handling.
These requirements create higher entry costs than those associated with many chemical generics. They also create supply-chain exposure. A competitor must demonstrate consistent product performance across batches and maintain a reliable supply of plasma-derived raw materials.
What is the Orange Book and Purple Book status of ARTISS?
ARTISS should be analyzed as a biologic rather than as a conventional Orange Book drug.
| Regulatory question |
ARTISS assessment |
| Orange Book-listed drug patents |
Not the primary regulatory framework |
| ANDA eligibility |
Not the normal pathway |
| Paragraph IV litigation |
Not the expected challenge mechanism |
| Purple Book relevance |
Yes, as a licensed biologic |
| Biosimilar substitution |
No established automatic substitution framework for ARTISS |
| Reference-product exclusivity |
Approximately 12 years from 2008 approval |
| Interchangeability |
No publicly established interchangeable ARTISS biosimilar |
The absence of a conventional Paragraph IV pathway reduces the probability of a sudden, patent-driven generic launch. Competition is more likely to emerge through an independently developed fibrin sealant or through a biosimilar-like product supported by extensive analytical and clinical evidence.
Which companies compete with ARTISS?
ARTISS competes in the fibrin sealant and surgical tissue-adhesion market. The most relevant products include Baxter’s TISSEEL and products marketed by Johnson & Johnson’s Ethicon, including EVICEL and VISTASEAL.
| Product |
Company |
Primary commercial positioning |
Competitive relationship with ARTISS |
| ARTISS |
Baxter |
Skin-graft adhesion and tissue adherence |
Direct competitor in reconstructive and burn surgery |
| TISSEEL |
Baxter |
Fibrin sealant for surgical hemostasis and sealing |
Same platform family, broader surgical use |
| EVICEL |
Ethicon |
Human fibrin sealant for hemostasis |
Competes for operating-room budgets and surgeon preference |
| VISTASEAL |
Ethicon |
Fibrin sealant for surgical hemostasis |
Competes in hospital sealant purchasing |
| Synthetic sealants and adhesives |
Multiple companies |
Tissue sealing or adhesion without human plasma-derived components |
Substitute technology, depending on procedure |
ARTISS has a narrower indication than products used for broad surgical hemostasis. That specialization can support physician familiarity in burn care and grafting while limiting total addressable volume.
How does ARTISS compare with TISSEEL and EVICEL?
ARTISS is differentiated primarily by indication and clinical workflow. TISSEEL is a broader fibrin-sealant platform used for hemostasis and tissue sealing. EVICEL is positioned around surgical hemostasis. ARTISS is most defensible in procedures where skin-graft adherence is the central clinical objective.
| Dimension |
ARTISS |
TISSEEL |
EVICEL |
| Core use |
Skin-graft adhesion |
Hemostasis and tissue sealing |
Hemostasis |
| Principal customer |
Burn, plastic, reconstructive, and surgical teams |
Broad hospital surgical departments |
Hospital surgical departments |
| Volume potential |
Narrower |
Broader |
Broader |
| Switching driver |
Graft adherence, handling, surgeon familiarity |
Hemostasis performance and price |
Hemostasis performance, formulary access, price |
| Main commercial risk |
Limited indication breadth |
Competitive pricing and formulary pressure |
Competitive pricing and hospital contracting |
ARTISS can benefit from Baxter’s existing hospital relationships and fibrin-sealant infrastructure. The same portfolio relationship can also create internal substitution risk if hospital protocols favor TISSEEL or if Baxter promotes a broader sealant product for a particular procedure.
What is the ARTISS litigation and settlement status?
No major publicly disclosed ARTISS-specific Paragraph IV litigation or settlement agreement is evident from the conventional generic-drug litigation framework. That outcome is consistent with ARTISS’s biologic status and the absence of a conventional Orange Book patent challenge.
The more relevant legal risks are likely to involve:
- Product liability claims.
- Manufacturing or contamination allegations.
- Labeling and informed-consent disputes.
- Patent disputes over fibrin-sealant manufacturing or applicator technology.
- Contractual disputes involving hospital supply and distribution.
- Regulatory enforcement involving plasma-derived biologic controls.
A lack of reported ARTISS-specific litigation does not mean that Baxter’s broader fibrin-sealant intellectual property or manufacturing assets are free of legal risk. It means that no major ARTISS-specific litigation event is incorporated into the commercial assessment based on the cited public sources.
What licensing deals affect ARTISS?
No ARTISS-specific licensing transaction is identified in Baxter’s cited public disclosures. ARTISS appears to be commercialized through Baxter’s own biologics and surgical-products infrastructure rather than through a publicly disclosed licensing arrangement.
The absence of a disclosed licensing deal has two implications. First, there is no visible royalty burden that can be assigned to ARTISS from public company reporting. Second, there is no disclosed partner whose termination, acquisition, or change in strategy would create an obvious product-specific commercial risk.
Baxter reports revenue by operating segment and product category rather than by individual brands such as ARTISS. Its public filings therefore do not provide a standalone ARTISS income statement or product-level margin profile (Baxter International Inc., 2024).
What is the financial trajectory of ARTISS?
ARTISS-specific revenue, unit volume, gross margin, and operating profit are not separately disclosed by Baxter. A precise financial trajectory cannot be calculated from public filings.
The available commercial indicators support a mature-product assessment:
| Financial factor |
Likely effect on ARTISS |
| Product age |
Limits exclusivity-driven price expansion |
| Specialized indication |
Supports clinical differentiation but constrains volume |
| Hospital purchasing |
Creates price and formulary pressure |
| Plasma-derived inputs |
Raises manufacturing and supply costs |
| Baxter distribution |
Supports market access and account retention |
| Competition |
Limits pricing power |
| Lack of public product-level reporting |
Prevents independent revenue modeling |
| Regulatory barriers |
Reduce rapid generic risk |
| Procedure volumes |
Drive demand more than consumer or chronic-use expansion |
ARTISS revenue is likely tied to burn treatment, reconstructive surgery, plastic surgery, trauma-related grafting, and institutional procedure volumes. Demand is therefore episodic and hospital-based rather than recurring through chronic prescriptions.
The product’s financial trajectory is more likely to show stable or gradual erosion than a sharp patent cliff. The reasons are structural:
- Statutory biologic exclusivity has expired.
- No large public biosimilar launch has been identified.
- The indication is specialized.
- Product usage depends on hospital protocols and surgeon preference.
- Human plasma-derived manufacturing limits low-cost entry.
- Competing sealants can win contracts without directly copying ARTISS.
What generic or biosimilar entry risks exist for ARTISS?
Near-term conventional generic entry risk is low because ARTISS is not a small-molecule drug with an ANDA and Paragraph IV pathway. Biosimilar risk is also limited by the technical and commercial complexity of fibrin-sealant products.
A potential entrant would need to address:
- Comparability of fibrinogen and thrombin activity.
- Stability during frozen storage and thawing.
- Viral safety and plasma sourcing.
- Delivery-device performance.
- Tissue-adhesion outcomes in the relevant surgical setting.
- Hospital procurement and surgeon adoption.
- Manufacturing scale and reimbursement.
The greater risk is substitution by an existing competitor, not an immediate low-price copy. Hospitals can switch products based on contract terms, availability, procedural preference, or broader formulary standardization.
What geographic markets support ARTISS?
ARTISS is primarily a hospital product with commercial relevance in the United States and other regulated markets where fibrin sealants are approved and reimbursed. Geographic performance depends on:
- Local approval status.
- Hospital procurement systems.
- Burn-center capacity.
- Reconstructive surgery volumes.
- Plasma-derived product requirements.
- Distributor and cold-chain coverage.
- National reimbursement rules.
The United States remains strategically important because Baxter has an established surgical-products presence and the product has an FDA-approved indication. European and other international markets may support demand, but country-level revenue and market-share data are not separately reported.
How strong is the ARTISS commercial and patent position?
ARTISS has a moderate commercial position and a limited visible exclusivity position.
Its commercial strengths are its FDA-approved indication, specialized clinical use, established supplier, and manufacturing complexity. Its weaknesses are the narrow indication, lack of publicly disclosed product-level financial growth, competition from fibrin sealants, and the expiration of statutory biologic exclusivity.
Its patent position cannot be characterized as a conventional high-value blocking estate. The practical barrier to entry is more likely to be regulatory, manufacturing, quality-related, and commercial than a single remaining patent term.
Key Takeaways
- ARTISS is Baxter’s human fibrin sealant for adherence of autologous skin grafts, especially in burn surgery.
- FDA approval occurred in 2008, placing the end of 12-year biologic exclusivity around 2020.
- ARTISS is not primarily an Orange Book or Paragraph IV product.
- No major ARTISS-specific biosimilar, generic challenge, litigation, or settlement is publicly identified in the cited sources.
- Baxter does not disclose ARTISS revenue separately, preventing a reliable product-level financial model.
- The product is likely a mature, specialized hospital biologic with gradual competitive erosion rather than a sharp generic cliff.
- The principal entry barriers are plasma-derived manufacturing, viral safety, formulation consistency, delivery systems, regulatory approval, and hospital adoption.
- Direct competition includes TISSEEL, EVICEL, and VISTASEAL, although their approved uses and commercial positioning differ.
FAQs
Is ARTISS a biologic or a medical device?
ARTISS is a biologic fibrin sealant. Its applicator and spray components are delivery systems, but the active product is regulated as a biologic.
Does ARTISS have biosimilar competition?
No established ARTISS biosimilar competitor is publicly identified in the cited sources. The technical requirements for plasma-derived fibrin sealants make development more complex than conventional generic entry.
Is ARTISS listed in the FDA Orange Book?
ARTISS is not analyzed like a conventional Orange Book small-molecule product. Its relevant regulatory framework is the biologic licensing system and the FDA Purple Book.
What is the main commercial difference between ARTISS and TISSEEL?
ARTISS is primarily used to adhere skin grafts to prepared wound beds. TISSEEL has broader positioning as a fibrin sealant for hemostasis and surgical sealing.
Can Baxter increase ARTISS revenue through a new indication?
A new indication could expand demand, but it would require regulatory support and clinical evidence. Publicly cited materials do not identify a current ARTISS-specific expansion program or separately reported development investment.
References
Baxter International Inc. (2024). 2023 annual report. https://www.baxter.com/investors
U.S. Food and Drug Administration. (2023). ARTISS fibrin sealant (human): Prescribing information. Baxter Healthcare Corporation. https://www.accessdata.fda.gov
U.S. Food and Drug Administration. (n.d.-a). Orange Book: Approved drug products with therapeutic equivalence evaluations. https://www.fda.gov/drugsatfda
U.S. Food and Drug Administration. (n.d.-b). Purple Book: Database of licensed biological products. https://purplebooksearch.fda.gov
U.S. Food and Drug Administration. (n.d.-c). Biosimilar and interchangeable biologic products. https://www.fda.gov/drugs/therapeutic-biologics-applications-bla/biosimilars
